At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 808 enrolled
Drug / intervention
Aclidinium bromide and formoterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, 4-week, Placebo-controlled, Double-blind, 6 Arm Parallel Group, Dose-finding Clinical Trial, to Assess the Efficacy, Safety and Pharmacokinetics of Three Different Doses of Formoterol Combined With the Inhaled Anticholinergic Aclidinium Bromide, Aclidinium Bromide Monotherapy and Formoterol Monotherapy All Administrated Once Daily by Inhalation Via Almirall Inhaler in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease.
In Brief
A Phase 2 clinical trial evaluating Aclidinium bromide and formoterol and Aclidinium bromide and formoterol placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 808 participants across 9 sites in 4 countries.
Detailed Summary
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Czechia, Poland, Russia
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionNov 2008
TodayJul 2026
First PostedFeb 29, 2008
Enrollment StartFeb 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.3 years ago
Interventions
Aclidinium bromide and formoteroldrug
once daily
Aclidinium bromide and formoterol placebodrug
once daily